Latest Period
n/a
Security Snapshot
iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) Institutional Ownership
CUSIP: 46565G104
13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
$10.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common stock, par value $0.001 per share
- Symbol
- ITOS
- Shares outstanding
- 10,000
- Price per share
- $10.15
- Price from insider filings
- $10.15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ITOS - iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share is tracked under CUSIP 46565G104.
- Latest finished 13F holder period is not available.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
- Reported value moved from $2,355 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
46565G104
Latest holder period
n/a
13F holders
13D/G owners
6
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 46565G104:
Significant Owners of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 28% | +87% | $78,563,988 | +$36,448,488 | 10,688,978 | +87% | EcoR1 Capital, LLC | 15 May 2025 |
| BlackRock Portfolio Management LLC | 6.1% | $17,124,228 | 2,329,827 | BlackRock Portfolio Management LLC | 31 Mar 2025 | |||
| BlackRock, Inc. | 5.7% | $16,018,737 | 2,179,420 | BlackRock, Inc. | 31 Mar 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | -50% | $15,690,824 | -$14,909,254 | 2,134,806 | -49% | RA Capital Management, L.P. | 15 May 2025 |
| MPM BioVentures 2014, L.P. | 4.7% | $13,259,371 | 1,803,996 | ANSBERT GADICKE | 13 May 2025 | |||
| TANG CAPITAL MANAGEMENT LLC | 100% | +900% | $101,100 | -$38,586,756 | 10,000 | -100% | TANG CAPITAL MANAGEMENT, LLC | 29 Aug 2025 |
Institutional Holders of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$2,355 | $10.15 | 0 |
| 2025 Q3 | 232 | $2,355 | -$376,633,348 | $10.15 | 1 |
| 2025 Q2 | 37,814,070 | $377,007,329 | +$70,828,909 | $9.97 | 134 |
| 2025 Q1 | 36,966,178 | $220,687,969 | +$13,034,816 | $5.97 | 128 |
| 2024 Q4 | 34,139,428 | $262,178,251 | -$45,399,619 | $7.68 | 133 |
| 2024 Q3 | 36,577,848 | $373,304,873 | -$1,622,214 | $10.21 | 145 |
| 2024 Q2 | 36,166,048 | $536,745,055 | +$26,093,561 | $14.84 | 132 |
| 2024 Q1 | 34,550,470 | $471,199,415 | -$28,496 | $13.64 | 128 |
| 2023 Q4 | 35,010,863 | $383,366,744 | -$6,188,505 | $10.95 | 131 |
| 2023 Q3 | 35,485,163 | $388,561,924 | +$7,227,919 | $10.95 | 141 |
| 2023 Q2 | 34,539,222 | $457,305,055 | -$20,449,873 | $13.24 | 140 |
| 2023 Q1 | 35,981,503 | $488,850,445 | -$5,820,065 | $13.61 | 149 |
| 2022 Q4 | 36,200,782 | $707,271,898 | -$15,821,418 | $19.53 | 144 |
| 2022 Q3 | 36,649,009 | $698,150,610 | -$16,258,800 | $19.05 | 133 |
| 2022 Q2 | 37,263,580 | $767,629,385 | +$2,327,841 | $20.60 | 147 |
| 2022 Q1 | 35,950,443 | $1,156,750,371 | +$80,764,252 | $32.18 | 154 |
| 2021 Q4 | 33,399,788 | $1,553,374,842 | +$104,747,384 | $46.56 | 115 |
| 2021 Q3 | 31,151,490 | $841,258,161 | +$47,292,624 | $27.00 | 76 |
| 2021 Q2 | 29,465,906 | $755,787,849 | -$27,400,681 | $25.65 | 82 |
| 2021 Q1 | 30,086,119 | $1,028,315,222 | +$89,149,616 | $34.18 | 78 |
| 2020 Q4 | 29,256,208 | $986,504,074 | +$60,467,414 | $33.82 | 72 |
| 2020 Q3 | 24,955,604 | $614,284,488 | +$614,284,486 | $24.67 | 54 |